Navigation Links
Early Opportunities to Set the Course for Successful Global Marketing Authorization, New Life Science Webinar Hosted by Xtalks
Date:9/13/2013

Toronto, Canada (PRWEB) September 13, 2013

Early planning of your marketing authorization strategy is crucial to the development of a comprehensive dossier filing and to avoiding potential delays or refusal to file down the line.

While achieving global marketing authorization approval is one of the end goals of the product development process, many companies don’t start considering their marketing application strategy until well into their Phase III program, losing out on opportunities to save time and help ensure accuracy downstream.

Common challenges and pitfalls that companies face as a result of gaps in planning their marketing authorization strategy early on may include a failure to understand global, regional, and local requirements for filing or a suboptimal presentation and analysis of data.

In this webinar, esteemed biostatistics and regulatory affairs professionals will share their insights on how to plan ahead, avoid costly delays and deal with quality issues. More specifically, speakers will cover how to: interpret the best landscape for a particular dossier; assessing the history of the compound; conduct a gap or SWOT analysis of the dossier, in addition to other key considerations

For more information about this event or to register, visit: http://xtalks.com/global-marketing-authorization.ashx.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx.

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/9/prweb11118299.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments
2. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
3. VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer
4. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
5. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
6. Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity
7. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
8. Researchers peek at the early evolution of sex chromosomes
9. Discuss Early Results of the DIAN Trial at CBIs 6th Annual Alzheimers Drug Development Summit
10. Early career distinction: Prestigious award recognizes physicists work in electron dynamics
11. JCI early table of contents for Sept. 4, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today reported its financial ... September 30, 2016. ... , SQI is a ... and commercializes proprietary technologies and products for advanced multiplexed diagnostics. ... million more than tripling prior years revenue. ...
(Date:12/6/2016)... ... December 06, 2016 , ... Discovering new clues to natural ... with lasers what’s happening in our brains. And searching for keys to our immune ... research being honored with the 2017 Edith and Peter O’Donnell Awards by ...
(Date:12/6/2016)... ... December 06, 2016 , ... Clinical Supplies ... has acquired the assets of Theorem Clinical Research - Clinical Supplies ("TCS"). ... trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials across ...
(Date:12/6/2016)... WARSAW, Ind. , Dec. 6, 2016 ... (the "Company") today announced the pricing terms of ... up to $1.25 billion aggregate purchase price (excluding accrued ... applicable settlement date and excluding fees and expenses ... of the debt securities identified in the table ...
Breaking Biology Technology:
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") ... million principal amount of its 1.414% senior unsecured notes due ... unsecured notes due 2026. The closing of ... to the satisfaction of customary closing conditions.  The notes will ... The Company intends to use the net proceeds from ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... 29, 2016 BioDirection, a privately held medical ... the objective detection of concussion and other traumatic brain ... completed a meeting with the U.S. Food and Drug ... Pre-Submission Package. During the meeting company representatives reviewed plans ... precursor to commencement of a planned pilot trial. ...
Breaking Biology News(10 mins):